Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $929K | $5.47M | $14.3M | $29.2M | $34.4M | $50.1M | $64.3M | $71.6M |
| Revenue growth | — | 489.2% | 160.6% | 104.9% | 17.8% | 45.7% | 28.1% | 11.5% |
| Gross profit | $383K | $4.20M | $11.3M | $23.3M | $28.4M | $42.4M | $55.2M | $58.8M |
| Gross margin | 41.2% | 76.8% | 79.2% | 79.6% | 82.4% | 84.5% | 85.8% | 82.1% |
| Operating income | -$13.8M | -$25.5M | -$42.7M | -$26.5M | -$27.5M | -$42.7M | -$56.6M | -$42.5M |
| Operating margin | -1489.9% | -466.4% | -299.2% | -90.8% | -79.9% | -85.1% | -88.1% | -59.4% |
| Net income | -$12.7M | -$25.1M | -$42.0M | -$26.6M | -$26.7M | -$35.4M | -$61.8M | -$48.6M |
| Net margin | -1370.8% | -458.6% | -294.7% | -90.9% | -77.5% | -70.6% | -96.3% | -67.8% |
| EPS (diluted) | $1.37 | $1.56 | $2.07 | $1.17 | $1.07 | -$1.40 | -$2.39 | -$1.74 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.0M | -$19.3M | -$22.7M | -$25.9M | -$19.1M | -$38.0M | -$48.9M | -$31.2M |
| Capital expenditures | $365K | $1.02M | $590K | $894K | $452K | $1.38M | $9.17M | $1.00M |
| Free cash flow | -$13.3M | -$20.3M | -$23.3M | -$26.8M | -$19.5M | -$39.4M | -$58.1M | -$32.2M |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $11.0M | $20.2M | $73.6M | $111M | $18.2M | $22.1M | $14.1M | $10.2M |
| Total assets | — | $25.8M | $82.5M | $126M | $98.3M | $112M | $79.7M | $56.4M |
| Total liabilities | — | $4.95M | $10.1M | $9.85M | $13.0M | $61.9M | $75.0M | $73.0M |
| Long-term debt | — | — | — | — | — | $39.8M | $42.2M | $0.00 |
| Shareholders' equity | $14.0M | $20.8M | $72.4M | $105M | $84.7M | $49.1M | $4.50M | -$16.6M |
| Retained earnings | — | -$153M | -$195M | -$221M | -$263M | -$298M | -$360M | -$408M |
| Shares (wtd avg diluted) | 9.33M | 16.1M | 20.3M | 22.7M | 25.0M | 25.3M | 25.9M | 27.9M |
Every figure is extracted from AVITA Medical, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.